Rameswara Segi Reddy

Rameswara Segi Reddy serves as a Post-doctoral Researcher (academic rank: Researcher) within the Nuffield Department of Medicine at the University of Oxford, affiliated with the Rabies Vaccine Manufacturing research group. His work bridges fundamental immunology and translational vaccine development, with a focus on improving global vaccine access through innovative manufacturing and delivery approaches.

Dr. Reddy's research spans three critical domains: vaccine platform development (malaria R21/Matrix-M candidate, rabies manufacturing, mRNA delivery systems), immune mechanism analysis (antibody repertoire studies, MAIT cell functions in vaccine reactogenicity), and infectious disease complications (tuberculosis in autoimmune disorders). His expertise in serological profiling and novel delivery systems like programmable microcapsules directly addresses challenges in single-shot immunization for hard-to-reach populations.

His 2025 publications reveal a cohesive research program advancing both specific vaccine candidates and fundamental immunological understanding. The malaria antibody study informs efficacy optimization, the tuberculosis-autoimmunity work identifies clinical risk factors, and the mRNA/MAIT cell research solves critical safety barriers—collectively strengthening global vaccine pipelines from bench to bedside.

While specific grant awards aren't detailed, Dr. Reddy's high-impact publications indicate robust funding support, likely through Oxford's major vaccine initiatives. His role emphasizes technical execution within team science frameworks, collaborating across Oxford's Jenner Institute, Biomedical Engineering, and global health networks to accelerate vaccine deployment.

The Rabies Vaccine Manufacturing group provides specialized infrastructure for viral vector production and novel delivery systems. Dr. Reddy's work here contributes to Oxford's legacy in transformative vaccine development, evidenced by their malaria microcapsule breakthrough and the life-saving impact of Oxford's prior COVID-19 vaccine. This environment fosters innovation from basic research through manufacturing scale-up for global distribution.